Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure.

Kyoichi KairaKunihiko KobayashiAyako ShionoOu YamaguchiKosuke HashimotoAtsuto MouriShun ShinomiyaYu MiuraHisao ImaiHiroshi Kagamu

Published in: Thoracic cancer (2021)

EGFR-TKI rechallenge immediately after PD-1 blockade treatment was identified as an effective therapy for NSCLC patients with resistance to EGFR-TKIs.

Keyphrases

tyrosine kinase
small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
randomized controlled trial
systematic review
brain metastases
chronic myeloid leukemia
smoking cessation